| Malignant Major Salivary Gland Neoplasm studied in …STUDIED_INderived10 of 20show all (up to 200) |
|---|
| → studied in | NCT04704661Phase 1 · active not recruiting Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00588770Phase 3 · active not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04576091Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05408845Phase 2 · recruiting Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01365169NA · recruiting Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (9 active) | — | — | Major Salivary Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895735Phase 2 · active not recruiting MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Major Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870762Phase 2 · recruiting Customized 3D Printed Oral Stents During Head and Neck Radiotherapy · condition mapped ONTOLOGY_EXACT · 20 trials mapped (9 active) | — | — | Malignant Parotid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02628067Phase 2 · active not recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Parotid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00405405Phase 1 · completed Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer · condition mapped CURATED_BROADER · 20 trials mapped (9 active) | — | — | Malignant Parotid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |